Intellia Therapeutics Inc
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.


Last Trade
0.03 (0.07%)
B/A Size

Market Hours

Closing Price
Day's Change
2.32 (5.78%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

SeaWorld stock sinks as earnings and attendance miss expectations, but revenue per guest reaches record

9:08 am ET November 9, 2022 (MarketWatch)

Shares of SeaWorld Entertainment Inc. sank 8.2% in premarket trading Wednesday after the theme park operator reported third-quarter results that missed expectations, as record revenue per guest wasn't enough to offset attendance that came up below forecasts due in part to adverse weather. Net income rose to $134.6 million, or $1.99 a share, from $102.1 million, or $1.28 a share, in the year-ago period. The FactSet consensus for earnings per share was $2.12. Revenue grew 8.4% to $565.2 million, but was below the FactSet consensus of $573.7 million, as admissions revenue rose 5.7% and food, merchandise and other revenue jumped 12.1%. Attendance was up 1.5% from a year ago to 7.3 million guests, but missed the FactSet consensus of 7.7 million. Compared with the same period of pre-pandemic 2019, attendance was down 9.7%. Total revenue per capita increased 6.8% to a record $77.05, above the FactSet consensus of $74.50, while admission revenue per capital rose 4.1% to a record $42.75, beating expectations of $41.60. "We had a meaningful impact from adverse weather in the quarter, including Hurricane Ian, that we estimate led to 90,000 less guest visits during the quarter; international and group visitation are still not back to pre-Covid levels; our staffing is still not at optimized levels; and inflationary pressures continue to impact our costs," said Chief Executive Mark Swanson. The stock has gained 7.2% over the past three months through Tuesday, while the S&P 500 has shed 7.1%.

-Tomi Kilgore


(END) Dow Jones Newswires

November 09, 2022 09:08 ET (14:08 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.